Afsaneh Barzi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2409891/publications.pdf

Version: 2024-02-01

70 papers	4,620 citations	361296 20 h-index	114418 63 g-index
70 all docs	70 docs citations	70 times ranked	9468 citing authors

#	Article	IF	Citations
1	Colorectal cancer statistics, 2017. Ca-A Cancer Journal for Clinicians, 2017, 67, 177-193.	157.7	3,300
2	Molecular Pathways: Estrogen Pathway in Colorectal Cancer. Clinical Cancer Research, 2013, 19, 5842-5848.	3.2	181
3	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncology, The, 2019, 20, 1070-1082.	5.1	169
4	Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treatment Reviews, 2018, 66, 15-22.	3.4	149
5	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clinical Cancer Research, 2020, 26, 5943-5951.	3.2	55
6	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	3.2	53
7	Comparative Effectiveness of Screening Strategies for Lynch Syndrome. Journal of the National Cancer Institute, 2015, 107, .	3.0	44
8	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochemical and Biophysical Research Communications, 2018, 500, 621-625.	1.0	44
9	Comparative effectiveness of screening strategies for colorectal cancer. Cancer, 2017, 123, 1516-1527.	2.0	41
10	Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. Clinical Colorectal Cancer, 2018, 17, e751-e761.	1.0	37
11	Myelodysplastic syndromes: A practical approach to diagnosis and treatment. Cleveland Clinic Journal of Medicine, 2010, 77, 37-44.	0.6	33
12	Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. European Journal of Cancer, 2019, 107, 115-123.	1.3	33
13	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas, 2020, 49, 193-200.	0.5	26
14	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget, 2016, 7, 53668-53678.	0.8	26
15	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Molecular Cancer Therapeutics, 2015, 14, 2401-2408.	1.9	25
16	Stomach Cancer Disparity among Korean Americans by Tumor Characteristics: Comparison with Non-Hispanic Whites, Japanese Americans, South Koreans, and Japanese. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 587-596.	1.1	25
17	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€“Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clinical Colorectal Cancer, 2018, 17, e395-e414.	1.0	25
18	Timeliness of Adjuvant Chemotherapy for Stage III Adenocarcinoma of the Colon: A Measure of Quality of Care. Clinical Colorectal Cancer, 2013, 12, 275-279.	1.0	24

#	Article	IF	Citations
19	Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. European Journal of Cancer, 2020, 130, 219-227.	1.3	24
20	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. European Journal of Cancer, 2017, 86, 197-206.	1.3	22
21	Trends in colorectal cancer mortality in hispanics: a SEER analysis. Oncotarget, 2017, 8, 108771-108777.	0.8	20
22	DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer, 2017, 123, 3732-3743.	2.0	19
23	MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaâ€"Trial in Progress.. Journal of Clinical Oncology, 2021, 39, TPS252-TPS252.	0.8	16
24	Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort. Cancers, 2021, 13, 3476.	1.7	13
25	Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opinion on Biological Therapy, 2014, 14, 1319-1332.	1.4	12
26	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. European Journal of Cancer, 2019, 107, 100-114.	1.3	12
27	Angiogenesis-related agents in esophageal cancer. Expert Opinion on Biological Therapy, 2012, 12, 1335-1345.	1.4	11
28	Primary tumor location and survival in colorectal cancer: A retrospective cohort study. World Journal of Gastrointestinal Oncology, 2020, 12, 405-423.	0.8	11
29	Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. Oncologist, 2022, 27, 579-586.	1.9	11
30	Single nucleotide polymorphisms in the IGFâ€IRS pathway are associated with outcome in mCRC patients enrolled in the FIREâ€3 trial. International Journal of Cancer, 2017, 141, 383-392.	2.3	10
31	Time from Diagnosis and Correlates of Health-Related Quality of Life among Young Adult Colorectal Cancer Survivors. Cancers, 2021, 13, 4045.	1.7	10
32	Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. Clinical Colorectal Cancer, 2016, 15, e221-e227.	1.0	9
33	Impacts of the SARS-CoV-2 Pandemic on Young Adult Colorectal Cancer Survivors. Journal of Adolescent and Young Adult Oncology, 2022, 11, 229-233.	0.7	9
34	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatinâ€based chemotherapy in patients with metastatic colorectal cancer. Cancer, 2017, 123, 4506-4514.	2.0	8
35	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2018, 18, 623-632.	0.9	8
36	Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma. Cancer Control, 2019, 26, 107327481984764.	0.7	8

#	Article	IF	Citations
37	Genetic variants in CCL5 and CCR5 genes and serum VEGFâ€A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. International Journal of Cancer, 2019, 144, 2567-2577.	2.3	8
38	SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.. Journal of Clinical Oncology, 2017, 35, 4016-4016.	0.8	8
39	The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2020, 38, e16686-e16686.	0.8	7
40	Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 428-434.	0.6	6
41	Tertiary Care Multidisciplinary Teams Associated with Improved Survival in Rectal Cancer Patients: A Comparative Study. American Surgeon, 2018, 84, 1645-1649.	0.4	5
42	Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature. Frontiers in Oncology, 2018, 8, 259.	1.3	5
43	Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims. Archives of Osteoporosis, 2019, 14, 83.	1.0	5
44	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist, 2021, 26, 610-618.	1.9	5
45	Novel Program Offering Remote, Asynchronous Subspecialist Input in Thoracic Oncology: Early Experience and Insights Gained During the COVID-19 Pandemic. JCO Oncology Practice, 2022, 18, e537-e550.	1.4	5
46	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer, 2019, 125, 3853-3863.	2.0	4
47	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers, 2020, 12, 1742.	1.7	4
48	Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. Cancer Genomics and Proteomics, 2021, 18, 317-324.	1.0	4
49	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 459.e15-459.e24.	0.8	3
50	Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies. Seminars in Oncology, 2018, 45, 133-150.	0.8	3
51	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics Journal, 2021, 21, 285-295.	0.9	3
52	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. Scientific Reports, 2021, 11, 12191.	1.6	3
53	Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey. Cancers, 2021, 13, 5467.	1.7	3
54	Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. Cost Effectiveness and Resource Allocation, 2018, 16, 30.	0.6	2

#	Article	IF	Citations
55	Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. Oncologist, 2020, 25, e1879-e1885.	1.9	2
56	Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer. Journal of Adolescent and Young Adult Oncology, 2020, 10, 336-341.	0.7	2
57	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 12106-12106.	0.8	2
58	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2018, 36, 3576-3576.	0.8	2
59	Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Pharmacogenetics and Genomics, 2021, 31, 10-16.	0.7	2
60	Immunotherapeutic Strategies for Colon Cancer: Monoclonal Antibody Therapy. Current Colorectal Cancer Reports, 2015, 11, 84-91.	1.0	1
61	Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.. Journal of Clinical Oncology, 2017, 35, 3585-3585.	0.8	1
62	How to optimize cancer therapy when coronavirus hits the fan. American Journal of Managed Care, 2020, 26, SP167.	0.8	1
63	Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. BMJ Open Gastroenterology, 2020, 7, e000483.	1.1	1
64	Lost in Translation: The Patient-Physician Relationship in the Molecular Era. Journal of Palliative Medicine, 2015, 18, 987-988.	0.6	0
65	We Don't Know What We Don't Know About Adolescent and Young Adult Patients with Familial Adenomatous Polyposis-Related Colorectal Cancer. Journal of Adolescent and Young Adult Oncology, 2015, 4, 105-107.	0.7	0
66	Health-related quality of life and time from diagnosis among young adult colorectal cancer survivors.. Journal of Clinical Oncology, 2021, 39, 34-34.	0.8	0
67	Molecular classification of cancers with an uncertain diagnosis as candidates for immunotherapy.. Journal of Clinical Oncology, 2017, 35, e23183-e23183.	0.8	0
68	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. Journal of Clinical Oncology, 2018, 36, 4098-4098.	0.8	0
69	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. Journal of Clinical Oncology, 2019, 37, 564-564.	0.8	0
70	Cost-effectiveness of genomic testing for colorectal cancer: are we there yet?. Oncology, 2015, 29, 183-4; 186.	0.4	0